Dr. Vaklavas is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Huntsman Cancer Institute
2000, Circle of Hope RS2509
Salt Lake City, UT 84112Phone+1 713-231-8086
Education & Training
University of Alabama Medical CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 2006 - 2009
Aristotle University of Thessaloniki School of MedicineClass of 2001
Certifications & Licensure
UT State Medical License 2019 - 2026
AL State Medical License 2010 - 2019- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women Start of enrollment: 2014 Mar 11
- Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer Start of enrollment: 2014 Jan 30
Publications & Presentations
PubMed
- 6 citationsDatopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.Rebecca A Shatsky, Meghna S Trivedi, Christina Yau, Rita Nanda, Hope S Rugo
Nature Medicine. 2024-12-01 - 2 citationsDatopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.Katia Khoury, Jane L Meisel, Christina Yau, Hope S Rugo, Rita Nanda
Nature Medicine. 2024-12-01 - 1 citationsTOWARDS Study: Patient-Derived Xenograft Engraftment Predicts Poor Survival in Patients With Newly Diagnosed Triple-Negative Breast Cancer.Christos Vaklavas, Cindy B Matsen, Zhengtao Chu, Kenneth M Boucher, Sandra D Scherer
JCO Precision Oncology. 2024-07-01
Press Mentions
New Tool Predicts Severity of TNBCSeptember 11th, 2024- Researchers Develop Mechanism That Predicts Severity of Aggressive Form of Breast CancerSeptember 5th, 2024
- Biomarker Testing Will Fuel Next Wave of Treatment Innovations in Breast CancerJune 10th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
